BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 25295500)

  • 21. Treatment of an infant with X-linked severe combined immunodeficiency (SCID-X1) by gene therapy in Australia.
    Ginn SL; Curtin JA; Kramer B; Smyth CM; Wong M; Kakakios A; McCowage GB; Watson D; Alexander SI; Latham M; Cunningham SC; Zheng M; Hobson L; Rowe PB; Fischer A; Cavazzana-Calvo M; Hacein-Bey-Abina S; Alexander IE
    Med J Aust; 2005 May; 182(9):458-63. PubMed ID: 15865589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correction of SCID-X1 using an enhancerless Vav promoter.
    Almarza E; Zhang F; Santilli G; Blundell MP; Howe SJ; Thornhill SI; Bueren JA; Thrasher AJ
    Hum Gene Ther; 2011 Mar; 22(3):263-70. PubMed ID: 20887212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy.
    Deichmann A; Hacein-Bey-Abina S; Schmidt M; Garrigue A; Brugman MH; Hu J; Glimm H; Gyapay G; Prum B; Fraser CC; Fischer N; Schwarzwaelder K; Siegler ML; de Ridder D; Pike-Overzet K; Howe SJ; Thrasher AJ; Wagemaker G; Abel U; Staal FJ; Delabesse E; Villeval JL; Aronow B; Hue C; Prinz C; Wissler M; Klanke C; Weissenbach J; Alexander I; Fischer A; von Kalle C; Cavazzana-Calvo M
    J Clin Invest; 2007 Aug; 117(8):2225-32. PubMed ID: 17671652
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Rajawat YS; Humbert O; Cook SM; Radtke S; Pande D; Enstrom M; Wohlfahrt ME; Kiem HP
    Hum Gene Ther; 2021 Jan; 32(1-2):113-127. PubMed ID: 32741228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transduction of human CD34+ repopulating cells with a self-inactivating lentiviral vector for SCID-X1 produced at clinical scale by a stable cell line.
    Greene MR; Lockey T; Mehta PK; Kim YS; Eldridge PW; Gray JT; Sorrentino BP
    Hum Gene Ther Methods; 2012 Oct; 23(5):297-308. PubMed ID: 23075105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nuclease-free Adeno-Associated Virus-Mediated Il2rg Gene Editing in X-SCID Mice.
    Hiramoto T; Li LB; Funk SE; Hirata RK; Russell DW
    Mol Ther; 2018 May; 26(5):1255-1265. PubMed ID: 29606506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells.
    Zhang F; Thornhill SI; Howe SJ; Ulaganathan M; Schambach A; Sinclair J; Kinnon C; Gaspar HB; Antoniou M; Thrasher AJ
    Blood; 2007 Sep; 110(5):1448-57. PubMed ID: 17456723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Faster T-cell development following gene therapy compared with haploidentical HSCT in the treatment of SCID-X1.
    Touzot F; Moshous D; Creidy R; Neven B; Frange P; Cros G; Caccavelli L; Blondeau J; Magnani A; Luby JM; Ternaux B; Picard C; Blanche S; Fischer A; Hacein-Bey-Abina S; Cavazzana M
    Blood; 2015 Jun; 125(23):3563-9. PubMed ID: 25869287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phage phiC31 integrase-mediated genomic integration of the common cytokine receptor gamma chain in human T-cell lines.
    Ishikawa Y; Tanaka N; Murakami K; Uchiyama T; Kumaki S; Tsuchiya S; Kugoh H; Oshimura M; Calos MP; Sugamura K
    J Gene Med; 2006 May; 8(5):646-53. PubMed ID: 16508910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Analysis of gammac-dependent cytokines-mediated immunoregulation].
    Asao H
    Rinsho Byori; 2007 Jan; 55(1):51-8. PubMed ID: 17319491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene therapy for severe combined immunodeficiencies and beyond.
    Fischer A; Hacein-Bey-Abina S
    J Exp Med; 2020 Jan; 217(2):. PubMed ID: 31826240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy.
    Pike-Overzet K; van der Burg M; Wagemaker G; van Dongen JJ; Staal FJ
    Mol Ther; 2007 Nov; 15(11):1910-6. PubMed ID: 17726455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning.
    Huston MW; van Til NP; Visser TP; Arshad S; Brugman MH; Cattoglio C; Nowrouzi A; Li Y; Schambach A; Schmidt M; Baum C; von Kalle C; Mavilio F; Zhang F; Blundell MP; Thrasher AJ; Verstegen MM; Wagemaker G
    Mol Ther; 2011 Oct; 19(10):1867-77. PubMed ID: 21750532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune Reconstitution After Gene Therapy Approaches in Patients With X-Linked Severe Combined Immunodeficiency Disease.
    Blanco E; Izotova N; Booth C; Thrasher AJ
    Front Immunol; 2020; 11():608653. PubMed ID: 33329605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene correction for SCID-X1 in long-term hematopoietic stem cells.
    Pavel-Dinu M; Wiebking V; Dejene BT; Srifa W; Mantri S; Nicolas CE; Lee C; Bao G; Kildebeck EJ; Punjya N; Sindhu C; Inlay MA; Saxena N; DeRavin SS; Malech H; Roncarolo MG; Weinberg KI; Porteus MH
    Nat Commun; 2019 Apr; 10(1):1634. PubMed ID: 30967552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
    Hacein-Bey-Abina S; Von Kalle C; Schmidt M; McCormack MP; Wulffraat N; Leboulch P; Lim A; Osborne CS; Pawliuk R; Morillon E; Sorensen R; Forster A; Fraser P; Cohen JI; de Saint Basile G; Alexander I; Wintergerst U; Frebourg T; Aurias A; Stoppa-Lyonnet D; Romana S; Radford-Weiss I; Gross F; Valensi F; Delabesse E; Macintyre E; Sigaux F; Soulier J; Leiva LE; Wissler M; Prinz C; Rabbitts TH; Le Deist F; Fischer A; Cavazzana-Calvo M
    Science; 2003 Oct; 302(5644):415-9. PubMed ID: 14564000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combating oncogene activation associated with retrovirus-mediated gene therapy of X-linked severe combined immunodeficiency.
    Strauss BE; Costanzi-Strauss E
    Braz J Med Biol Res; 2007 May; 40(5):601-13. PubMed ID: 17464421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial.
    Wang GP; Berry CC; Malani N; Leboulch P; Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Bushman FD
    Blood; 2010 Jun; 115(22):4356-66. PubMed ID: 20228274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The evolution of gene therapy in X-linked severe combined immunodeficiency.
    Rans TS; England R
    Ann Allergy Asthma Immunol; 2009 May; 102(5):357-62; quiz 363-5, 402. PubMed ID: 19492655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.
    Hacein-Bey-Abina S; Garrigue A; Wang GP; Soulier J; Lim A; Morillon E; Clappier E; Caccavelli L; Delabesse E; Beldjord K; Asnafi V; MacIntyre E; Dal Cortivo L; Radford I; Brousse N; Sigaux F; Moshous D; Hauer J; Borkhardt A; Belohradsky BH; Wintergerst U; Velez MC; Leiva L; Sorensen R; Wulffraat N; Blanche S; Bushman FD; Fischer A; Cavazzana-Calvo M
    J Clin Invest; 2008 Sep; 118(9):3132-42. PubMed ID: 18688285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.